VivoSeq
Gastroenterology

Lymphocytic Colitis

2

Pipeline Programs↗

0

Active Trials↗

2

Companies Involved↗

Lymphocytic Colitis is an early-stage landscape with 2 programs across 2 companies. The most active players are Takeda, Salix. 2 programs are in Phase 3.

Intelligence

Pipeline Metrics

Competitive Density

16/100

Pipeline Velocity

0/100

Mech. Concentration

50/100

Completion Rate

67/100

Attrition Rate

33/100

Competition

Competitive Landscape

Bubble size = clinical trials

Approved
Phase 3
Phase 2
Phase 1
Preclinical

Key Players

Top Companies Companies ranked by the number of pipeline programs they run for this disease.

Takeda logo

Takeda

1 program

Phase 3S

Salix

1 program

Phase 3

Pipeline

Programs by Phase

Preclinical
No programs
Phase 1
No programs
Phase 2
No programs
Phase 32

Mesalamine

Takeda

Budesonide

Salix

Approved
No programs

Analysis

Trial Status

3

clinical trials

Completed2 · 67%
Terminated1 · 33%

Clinical Trials

Trial Activity

Budesonide Versus Placebo for the Treatment of Lymphocytic Colitis
Terminated·MMayo Clinic·Phase 2/3·NCT00217022·16 enrolled
Budesonide Treatment for Lymphocytic Colitis
Completed·TTechnische Universität Dresden·Phase 3·NCT00180050·40 enrolled
Budesonide Versus Mesalazine Versus Placebo in Lymphocytic Colitis
Completed·—·Phase 3·NCT01209208·57 enrolled

Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)